Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02FEA
|
||||
| Former ID |
DNC011273
|
||||
| Drug Name |
FENDILINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Coronary heart disease [ICD9: 414; ICD10:I25.1] | Withdrawn from market | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H25N
|
||||
| Canonical SMILES |
CC(C1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
|
||||
| InChI |
1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3
|
||||
| InChIKey |
NMKSAYKQLCHXDK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 13042-18-7
|
||||
| PubChem Compound ID | |||||
| SuperDrug ATC ID |
C08EA01
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2B receptor | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Value of fendiline in the treatment of patients with stable angina pectoris. Pol Tyg Lek. 1987 Nov 16;42(46):1456-8. | ||||
| REF 2 | J Med Chem. 2010 Nov 11;53(21):7573-86.Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.